| Status | Study |
| Recruiting |
Study Name: CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML Condition: Acute Myelogenous Leukemia Acute Myeloid Leukemia Acute My Date: 2016-10-23 Interventions: Biological: anti-CD33 CAR-NK cells The allogeneic NK cells (NK-92 cell line for clinical use) are engine |
| Completed |
Study Name: Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Condition: Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leuk Date: 2014-05-20 Interventions: Drug: choline magnesium trisalicylate |
| Terminated |
Study Name: AML Therapy With Irradiated Allogeneic Cells Condition: Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leuk Date: 2014-04-02 Interventions: Drug: fludarabine phosphate Gi |
| Active, not recruiting |
Study Name: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Condition: Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia Date: 2014-01-28 Interventions: Drug: MEK inhibitor MEK162 Giv |
| Terminated |
Study Name: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Condition: Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leuk Date: 2013-11-25 Interventions: Drug: ixazomib Given PO Other Names: |
| Active, not recruiting |
Study Name: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Condition: Adult Acute Erythroid Leukemia (M6) Adult Acute Megakaryoblastic Leukemia (M7) Date: 2013-11-25 Interventions: Drug: liposomal cytarabine-daunorubicin CPX-351 |
| Active, not recruiting |
Study Name: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Condition: Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leuk Date: 2013-07-17 Interventions: Drug: lenalidomide Given PO |
| Active, not recruiting |
Study Name: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay Condition: Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leuk Date: 2013-06-04 Interventions: Other: antitumor drug screening assay |
| Active, not recruiting |
Study Name: Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Condition: Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leuk Date: 2013-05-06 Interventions: Drug: metformin hydrochloride |
| Active, not recruiting |
Study Name: Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia Condition: Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Monoblastic Leukemia (M5a) Date: 2013-04-19 Interventions: Drug: azacitidine Given IV or |